Gilead Sciences Yescarta for Relapsed or Refractory Indolent Follicula Lymphoma
If Kite Pharma - a Gilead Sciences (GILD) company, had been acquired by any firm other than Gilead the stock would have gained at least 20% because of the news announced a few days ago.
Kite Pharma announced outstanding Yescarta® (axicabtagene ciloleucel) results from the pivotal ZUMA-5 trial.
At a minimum follow . . .
This content is for paid subscribers.
Impacting News June 16, 2021